January 1, 2005The Journal of Maternal-Fetal & Neonatal Medicine
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia
Authors
Discussion
Loading...
Member takes
Implication
Longitudinal case-control study demonstrates elevated plasma sVEGFR-1 weeks before clinical onset in pre-eclampsia, indicating its potential utility as an early predictive biomarker.
Key Points
- To determine whether maternal plasma concentrations of soluble vascular endothelial growth factor receptor-1 change prior to the clinical onset of pre-eclampsia.
- Conducted a longitudinal case-control study comparing normal pregnant women (n = 44) with patients who developed pre-eclampsia (n = 44).
- Collected serial plasma samples across six gestational intervals (7-16, 16-24, 24-28, 28-32, 32-36, and >37 weeks) and quantified sVEGFR-1 using enzyme-linked immunoassay.
- Stratified pre-eclamptic samples by time to diagnosis (clinical manifestation, 2-5, 6-10, 11-16, and 17-25 weeks prior) and onset timing (early-onset at ≤34 weeks vs. late-onset at >34 weeks).
- Mean plasma sVEGFR-1 was significantly higher in pre-eclamptic women at 24-28 (p = 0.02), 28-32 (p < 0.001), and 32-37 weeks (p < 0.001), but did not differ at 7-16 weeks (p = 0.1) or 16-24 weeks (p = 0.9).
- Elevation in sVEGFR-1 significantly preceded clinical diagnosis at 6-10 weeks prior (mean 8.2 weeks; p = 0.002) and 2-5 weeks prior (mean 3.8 weeks; p < 0.001), continuing through clinical manifestation (p < 0.001).
- Early-onset pre-eclampsia displayed elevated sVEGFR-1 earlier at 24-28 weeks (mean 26.4 weeks; p = 0.008), whereas late-onset pre-eclampsia showed elevation at 28-32 weeks (mean 30.2 weeks; p < 0.001).
Cite This Study
Chaiworapongsa et al. (2005) studied this question.